<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic therapy for vulvar abscess</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic therapy for vulvar abscess</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic therapy for vulvar abscess</div><div class="cntnt"><table cellspacing="0"><colgroup width="35%"></colgroup><colgroup width="65%"></colgroup> <tbody> <tr> <td class="subtitle1">Antibiotic(s)</td> <td class="subtitle1">Dosing (adult patients with normal organ function)</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Empiric oral antibiotic therapy options for vulvar abscess* (treatment is recommended for 5 to 7 days)</td> </tr> <tr> <td class="indent1"><strong>Preferred:</strong> <ul class="decimal_heading"> <li>Trimethoprim-sulfamethoxazole (co-trimoxazole)<sup>¶</sup> <strong>or</strong> </li> <li>Trimethoprim-sulfamethoxazole<sup>¶</sup> plus amoxicillin-clavulanate <strong>or</strong> </li> <li>Trimethoprim-sulfamethoxazole<sup>¶</sup> plus metronidazole </li> </ul> </td> <td class="divider_bottom" rowspan="3"> <ul> <li>Trimethoprim-sulfamethoxazole (co-trimoxazole): 1 to 2 DS tablets orally twice daily </li> <li>Amoxicillin-clavulanate: 875 mg orally twice daily </li> <li>Metronidazole: 500 mg orally 3 times daily </li> <li>Doxycycline: 100 mg orally twice daily </li> <li>Minocycline: 200 mg orally once, then 100 mg orally twice daily </li> <li>Clindamycin: 450 mg orally 3 times daily </li> <li>Ciprofloxacin: 500 mg orally twice daily </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Alternatives:</strong> <ul class="decimal_heading"> <li>Doxycycline plus amoxicillin-clavulanate <strong>or</strong> </li> <li>Doxycycline plus metronidazole <strong>or</strong> </li> <li>Minocycline plus amoxicillin-clavulanate <strong>or</strong> </li> <li>Minocycline plus metronidazole </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Less-preferred alternatives (according to local resistance patterns):</strong> <ul class="decimal_heading"> <li>Clindamycin<sup>Δ</sup> plus amoxicillin-clavulanate <strong>or</strong> </li> <li>Clindamycin<sup>Δ</sup> plus ciprofloxacin </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle2_left" colspan="2">Empiric intravenous antibiotic therapy options for severe vulvar abscess<sup>◊</sup></td> </tr> <tr> <td class="indent1">One of the following: <ul class="decimal_heading"> <li>Vancomycin </li> <li>Daptomycin </li> <li>Teicoplanin<sup>§</sup> (where available) </li> </ul> <strong>PLUS</strong> one of the following: <ul class="decimal_heading"> <li>Ampicillin-sulbactam </li> <li>Piperacillin-tazobactam<sup>¥</sup> </li> <li>Ceftriaxone plus metronidazole </li> <li>Ciprofloxacin plus metronidazole </li> <li>Levofloxacin plus metronidazole </li> </ul> </td> <td> <ul> <li>Vancomycin:<sup>‡</sup> <ul> <li>Loading dose (optional): 20 to 35 mg/kg IV once </li> <li>Initial maintenance dose and interval: Typically 15 to 20 mg/kg IV every 8 to 12 hours or determined by use of a locally validated initial dosing nomogram </li> <li>Subsequent dose and interval adjustments: Generally based on AUC-guided or trough-guided serum concentration monitoring </li> </ul> </li> <li>Daptomycin: 4 to 6 mg/kg IV every 24 hours </li> <li>Teicoplanin<sup>§</sup> (not available in the United States and Canada): <ul> <li>Loading dose: 6 mg/kg IV every 12 hours for 3 doses </li> <li>Maintenance dose: 6 mg/kg IV or IM once daily to achieve target trough concentration &gt;10 mg/L </li> </ul> </li> <li>Ampicillin-sulbactam: 3 g IV every 6 hours </li> <li>Piperacillin-tazobactam: 3.375 g IV every 6 hours or 4.5 g IV every 8 hours </li> <li>Ceftriaxone: 1 to 2 g IV every 24 hours </li> <li>Metronidazole: 500 mg IV every 8 hours </li> <li>Ciprofloxacin: 400 mg IV every 12 hours </li> <li>Levofloxacin: 750 mg IV every 24 hours </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">DS: double-strength (ie, trimethoprim 160 mg with sulfamethoxazole 800 mg per tablet); IV: intravenously; AUC: area under the plot of plasma concentration of a drug versus time; IM: intramuscularly; MRSA: methicillin-resistant <em>Staphylococcus aureus</em>.<br/>* Not all vulvar abscesses require antibiotic therapy; indications for empiric oral antibiotic therapy are discussed in the vulvar abscess topic within UpToDate.<br/>¶ Due to increasing rates of <em>Escherichia coli</em> resistance to trimethoprim-sulfamethoxazole (co-trimoxazole), local resistance patterns must be considered before using this antibiotic as empiric treatment.<br/>Δ Clindamycin has a higher risk of <em>Clostridioides</em> (formerly <em>Clostridium</em>) <em>difficile</em> infection and a higher rate of nonsusceptibility to MRSA; other regimens are generally preferred. Refer to the topics on treatment of MRSA for additional information.<br/><font class="lozenge">◊</font> IV therapy is warranted if any one of the following features are present: severe infection (eg, fever &gt;100.4°F [38°C] and chills with sustained tachycardia), rapid progression of erythema, proximity to an indwelling medical device such as a vascular graft, necrotizing fasciitis, or inability to tolerate oral medications. In general, in patients receiving IV therapy, discrete abscesses should be drained and specimens sent for culture and susceptibility testing. IV therapy can be switched to an oral regimen, preferably tailored to the culture and susceptibility results, after signs of infection begin to resolve. Total duration of therapy is typically 7 to 10 days.<br/>§ In areas outside of the United States and Canada where teicoplanin is available, some use it as the drug of choice for initial therapy of gram-positive pathogens, while others favor its use for patients with intolerance to vancomycin.<br/>¥ Risk of nephrotoxicity is increased when piperacillin-tazobactam is given in combination with vancomycin.<br/>‡ For severely ill patients, a vancomycin loading dose may be considered. Refer to the UpToDate clinical topic review of vancomycin dosing for guidance on individualizing the loading dose, sample dosing nomogram, and serum concentration monitoring.</div><div id="graphicVersion">Graphic 64305 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
